natgillin/translations-raw huggingface dataset:
One of the two studies showed a significant delay in the time to disability progression (31% risk reduction due to Betaferon) and in the time to becoming wheelchair bound (39%). 
U jednome od dva ispitivanja utvrđena je znatna vremenska odgoda progresije invalidnosti (smanjenje rizika od 31 % zbog uzimanja lijeka Betaferon) i vremena do pojave stupnja invalidnosti pri kojem je bolesnik vezan uz invalidska kolica (39 %).
Betaferon is available as a powder and solvent that are made up into a solution that supplies a dose of 250 micrograms. 
Betaferon je dostupan u obliku praška ili otapala od kojih se priprema otopina koja je dovoljna za dozu od 250 mikrograma.
Betaferon was shown to reduce the risk of developing clinically defined MS: 28% of the patients who received Betaferon developed MS, compared with 45% of those who received placebo. 
Utvrđeno je da lijek Betaferon umanjuje rizik od razvijanja klinički definirane multiple skleroze: u 28 % bolesnika koji su uzimali Betaferon razvila se multipla skleroza, u usporedbi s 45 % onih koji su uzimali placebo.
The active substance in Betaferon is the protein interferon beta-1b, one of a group of interferons that can be naturally produced by the body to help it fight against viruses and other attacks. 
Djelatna tvar lijeka Betaferon je interferon beta-1b, bjelančevina iz skupine interferona koju tijelo prirodno proizvodi i koja pomaže u borbi protiv virusa i drugih napada na tijelo.
Betaferon was also studied in 487 patients with a single demyelinating event, who received either Betaferon or placebo for two years. 
Lijek Betaferon ispitivan je i kod 487 bolesnika koji su doživjeli samo jedan događaj demijelinizacije i koji su dvije godine uzimali Betaferon ili placebo.
What benefits of Betaferon have been shown in studies? 
Koje su koristi od lijeka Betaferon utvrđene u ispitivanjima?
Betaferon contains the active substance interferon beta-1b. 
Betaferon sadrži djelatnu tvar interferon beta-1b.
Betaferon was studied over a two-year period in 338 patients with relapsing remitting MS who were able to walk unaided, where it was compared with placebo (a dummy treatment). 
Lijek Betaferon ispitivan je tijekom razdoblja od dvije godine u 338 bolesnika s relapsno-remitirajućim MS-om koji su mogli hodati bez pomoći i uspoređen je s placebom (prividnim liječenjem).
Betaferon treatment should be stopped in patients whose condition does not improve. 
Liječenje lijekom Betaferon treba prekinuti ako se stanje bolesnika ne poboljša.
Betaferon has also been studied in 1,657 patients in two studies of secondary progressive MS patients who were able to walk, where it was compared with placebo. 
Betaferon je također ispitivan u dvama ispitivanjima na 1 657 bolesnika oboljelih od sekundarno progresivnog MS-a koji su mogli hodati.
• who have experienced the signs of MS for the first time, and these are severe enough to need treatment with injected corticosteroids (anti-inflammatory medicines). 
• koji su prvi put iskusili znakove MS-a i ti su znakovi dovoljno jaki da ih je potrebno liječiti injekcijama kortikosteroida (protuupalnih lijekova).
How is Betaferon used? 
Kako djeluje Betaferon?
Betaferon is used when the patient is considered to be at high risk of developing MS. Before using Betaferon, doctors need to exclude other causes for the symptoms; 
Prije uporabe lijeka Betaferon liječnik mora isključiti druge uzroke simptoma;
For the full list of side effects and restrictions with Betaferon, see the package leaflet. 
Potpuni popis nuspojava i ograničenja zabilježenih pri primjeni lijeka Betaferon potražite u uputi o lijeku.
Date of first authorisation: 18 February 2019 
Datum prvog odobrenja: 18. veljače 2019
Prins Bernhardplein 200 1097JB Amsterdam Netherlands 
Prins Bernhardplein 200 1097JB Amsterdam Nizozemska
• an examination to check the nerves in your arms and legs 
• pregled za provjeru živaca Vaših ruku i nogu
ATC Code: A16AX06 
ATK oznaka: A16AX06
Weight loss, decreased appetite 
Gubitak težine, smanjen apetit
• Always take this medicine exactly as your doctor has told you. 
Uvijek primjenjujte ovaj lijek točno onako kako Vam je savjetovao liječnik.
Hard capsule 
Tvrda kapsula.
Hard capsule 84 capsules 84x1 capsules 
Tvrda kapsula 84 kapsule 84x1 kapsula
• measurement of vitamin B12 levels 
• mjerenje razine vitamina B12
The greatest prevalence was observed between 6 and 12 months. 
Najveća prevalencija primijećena je između 6 i
- if you are allergic to miglustat or any of the other ingredients of this medicine (listed in section 6). 
- ako ste alergični na miglustat ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.)
{MM/YYYY} 
<{MM/GGGG}>
You should not take Miglustat Dipharma if you are pregnant or thinking of becoming pregnant. 
Miglustat Dipharma ne smijete uzeti ako ste trudni ili ako namjeravate zatrudnjeti.
Miglustat Dipharma can be taken with or without food. 
Miglustat Dipharma se može uzeti s hranom ili bez nje.
This leaflet was last revised in {MM/YYYY} Other sources of information 
Ova uputa je zadnji puta revidirana u: {MM/GGGG}
20089 Quinto dè Stampi - Rozzano (MI) 
20089 Quinto dè Stampi - Rozzano (MI) Italija
Do not stop taking Miglustat Dipharma without talking to your doctor. 
Nemojte prestati uzimati Miglustat Dipharma bez razgovora s liječnikom.
They may lower the amount of Miglustat Dipharma in your body. 
To može sniziti količinu lijeka Miglustat Dipharma u Vašem tijelu.
If you do lose some weight when you start treatment with Miglustat Dipharma don't worry. 
Ako izgubite na težini kad počnete liječenje lijekom Miglustat Dipharma, ne brinite.
The tests will help the doctor decide whether these effects are due to your disease or other existing conditions, or due to side effects of Miglustat Dipharma (see section 4 for further details). 
Ove pretrage će pomoći liječniku ustanoviti jesu li ti učinci posljedica ove bolesti ili drugih postojećih bolesti ili su posljedica nuspojava lijeka Miglustat Dipharma (za daljnje pojedinosti vidjeti dio 4).
Most patients get one or more of these side effects mentioned above, usually at the start of treatment or at intervals during treatment. 
Kod većine bolesnika dođe do jedne ili više ovih nuspojava, obično na početku liječenja ili u razmacima tijekom liječenja.
Tell your doctor if you are taking medicines containing imiglucerase, which are sometimes used at the same time as Miglustat Dipharma. 
Obavijestite svog liječnika ako uzimate lijekove koji sadrže imiglucerazu, koji se ponekad uzimaju istodobno s lijekom Miglustat Dipharma.
Maximum plasma concentrations are reached about 2 hours after dose. 
Maksimalne koncentracije u plazmi dostignute su u roku od oko 2
If you get a slight tremor, usually trembling hands, seek medical advice from your doctor as soon as possible. 
Ako imate blagi tremor, koji se uobičajeno očituje drhtanjem ruku, zatražite savjet svog liječnika što je prije moguće.
The average half-life is 6-7 hours. 
Prosječni poluvijek je 6
Talk to your doctor or pharmacist before taking Miglustat Dipharma 
Obratite se svom liječniku ili ljekarniku prije nego uzmete Miglustat Dipharma
There are no pharmacokinetic data available in patients with liver impairment or in the elderly (> 70 years). 
Nema dostupnih farmakokinetičkih podataka za bolesnike s oštećenjem funkcije jetre ili za starije bolesnike (> 70 godina).
Miglustat has been used in clinical trials at doses ten times higher than the recommended dose: this caused decreases in white blood cells and other side effects similar to those described in section 4. 
Miglustat Dipharma je korišten u kliničkim ispitivanjima u deset puta većim dozama od preporučenih: to je uzrokovalo smanjenje broja bijelih krvnih stanica i druge nuspojave slične onima opisanima u dijelu 4.
• if you suffer from liver disease 
• ako patite od bolesti bubrega • ako patite od bolesti jetre
What Miglustat Dipharma looks like and contents of the pack 
Kako Miglustat Dipharma izgleda i sadržaj pakiranja
This study also indicated that miglustat has no or limited effect on the pharmacokinetics of imiglucerase. 
To ispitivanje ukazuje također na to da miglustat nema nikakav ili ima ograničen učinak na farmakokinetiku imigluceraze.
Among the 41 patients enrolled in the trial 14 patients were treated with miglustat for more than 3 years. 
Od 41 bolesnika uključenih u ispitivanje 14 bolesnika je liječeno miglustat duže od 3 godine.
PCTFE/PVC and Aluminium blister containing 12 (perforated unit dose) or 21 (non-perforated) capsules. 
PCTFE/PVC i aluminijska blister pakiranja koja sadrže 12 (perforirana jedinična doza) ili 21 (neperforirana) kapsulu.
Following administration of a single dose of 100 mg 14C-miglustat to healthy volunteers, 83% of the radioactivity was recovered in urine and 12% in faeces. 
7 sati.Nakon davanja jedne doze od 100 mg 14C-miglustata zdravim dobrovoljcima, 83% radioaktivno označenog lijeka izlučeno je u urinu a 12% u fecesu.
The efficacy of miglustat in children and adolescents aged 0-17 years with type 1 Gaucher disease has not been established. 
Djelotvornost miglustata kod djece i adolescenata u dobi od 0 do 17 godina s Gaucherovom bolesti tipa 1 nije ustanovljena.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. 
U sklopu svake kategorije učestalosti, nuspojave su prikazane prema padajućoj ozbiljnosti.
An open-label, non-comparative, 2-year study enrolled 42 patients with type 1 Gaucher disease, who had received a minimum of 3 years of ERT and who fulfilled criteria of stable disease for at least 2 years. 
Otvoreno, nekomparativno 2-godišnje ispitivanje uključivalo je 42 bolesnika s Gaucherovom bolesti tipa 1, koji su najmanje 3 godine primali ERT a koji su zadovoljavali kriterij stabilne bolesti od najmanje 2 godine.
What Miglustat Dipharma is and what it is used for 
Što je Miglustat Dipharma i za što se koristi
Data to support safety and efficacy of miglustat in Niemann-Pick type C disease come from a prospective open-label clinical trial and a retrospective survey. 
Podatci koji podupiru sigurnost i djelotvornost miglustat u Niemann-Pickovoj bolesti tipa C potječu iz prospektivnog otvorenog kliničkog ispitivanja i retrospektivne analize.
Since some patients have had tingling or numbness in the hands and feet, or a decrease in body weight, while taking Miglustat Dipharma, your doctor will perform the following tests before treatment and during treatment with Miglustat Dipharma: 
Budući da su neki bolesnici imali trnce ili ukočenost u rukama i stopalima ili smanjenje tjelesne težine tijekom uzimanja lijeka Miglustat Dipharma, vaš liječnik će prije i tijekom liječenja lijekom Miglustat
100 mg three times a day 100 mg twice a day 
200 mg triput dnevno 200 mg dvaput dnevno 100 mg triput dnevno 100 mg dvaput dnevno 100 mg jednom dnevno
In type 1 Gaucher disease, a substance called glucosylceramide is not removed from your body. 
Kod Gaucherove bolesti tipa 1 tvar zvana glukozilceramid se ne uklanja iz Vašeg tijela.
Miglustat Dipharma has negligible influence on the ability to drive and use machines. 
Miglustat Dipharma zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
In type 1 Gaucher disease, these tremors were described as an exaggerated physiological tremor of the hands. 
Ti su tremori opisani kao pretjerani fiziološki tremor ruku.
Regular monitoring of vitamin B12 level is recommended because of the high prevalence of vitamin B12 deficiency in patients with type 1 Gaucher disease. 
Preporučuje se redovito praćenje razine vitamina B12 zbog visoke prevalencije nedostatka vitamina B12
Limited data suggest that co-administration of miglustat and enzyme replacement with imiglucerase in patients with type 1 Gaucher disease may result in decreased exposure to miglustat (approximate reductions of 22% in Cmax and 14% in AUC were observed in a small parallel-group study). 
Ograničeni podatci ukazuju na to da istodobna primjena miglustata i enzimskog nadomjestka s imiglucerazom u bolesnika s Gaucherovom bolesti tipa 1 može za posljedicu imati smanjenu izloženost miglustatu (približno smanjenje od 22% u Cmax i 14% u AUC zabilježeno u malom ispitivanju s paralelnim skupinama).
Capsule content Magnesium stearate 
Sadržaj kapsule magnezijev stearat
Detailed information on this medicinal prodcut is available on the website of the European Medicines Agency http://www.ema.europa.eu 
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove http://www.ema.europa.eu.
Depression, insomnia, libido decreased 
Depresija, nesanica, smanjen libido
In addition, inhibitory action on a non-lysosomal glycosylceramidase has been demonstrated experimentally in vitro. 
Osim toga, inhibitorno djelovanje nelizosomalne glikozilceramidaze eksperimentalno se pokazalo in vitro.
In vitro, glucosylceramide synthase is inhibited by miglustat with an IC50 of 20-37 μM. 
In vitro, miglustat inhibira glukozilceramid sintazu sa IC50 koji iznosi 20-37 µM.
The survey included a case series of 66 patients treated with miglustat outside of the clinical trial for a mean duration of 1.5 years. 
Analiza je uključivala seriju slučajeva od 66 bolesnika liječenih miglustat izvan kliničkog ispitivanja u prosječnom trajanju od 1,5 godine.
Of these, 18 patients at baseline were within established therapeutic goals for liver and spleen volume, haemoglobin levels, and platelet counts, and 16 patients remained within all these therapeutic goals at month 24. 
Među njima je bilo 18 bolesnika s početnim volumenom jetre i slezene, razinama hemoglobina i brojem trombocita unutar utvrđenih terapijskih ciljeva, a 16 bolesnika je ostalo unutar svih tih terapijskih ciljeva u 24 mjesecu.
Your doctor will perform some tests before and during treatment with Miglustat Dipharma to assess this (see section 2). 
Liječnik će provesti neke pretrage prije i za vrijeme liječenja lijekom Miglustat Dipharma kako bi to procijenio (vidjeti dio 2).
Miglustat Dipharma contains the active substance miglustat which belongs to a group of medicines that affect metabolism. 
Miglustat Dipharma sadrži djelatnu tvar miglustat koja pripada skupini lijekova koji djeluju na metabolizam.
If you take more Miglustat Dipharma than you should 
Ako uzmete više lijeka Miglustat Dipharma nego što ste trebali
Miglustat is mainly eliminated by renal excretion, with urinary recovery of unchanged substance accounting for 70-80% of the dose. 
Miglustat se uglavnom eliminira izlučivanjem bubrezima, pri čemu se u urinu pronašlo 70-80% doze neizmijenjenog lijeka.
Miglustat Dipharma is only used when a patient is considered unsuitable for treatment with enzyme replacement therapy. 
Miglustat Dipharma se primjenjuje samo kada se smatra da bolesnik nije pogodan za enzimsko nadomjesno liječenje.
In clinical practice, miglustat-induced gastrointestinal events have been observed to respond to individualised diet modification (for example reduction of sucrose, lactose and other carbohydrate intake), to taking miglustat between meals, and/or to anti-diarrhoeal medicinal products such as loperamide. 
U kliničkoj praksi, primijećeno je da gastrointestinalni događaji potaknuti miglustatom reagiraju na individualiziranu prilagodbu prehrane (na primjer smanjeno uzimanje saharoze, laktoze i drugih ugljikohidrata), uzimanje miglustata između obroka, i/ili na lijekove protiv proljeva poput loperamida.
The most common adverse reactions reported in clinical trials with miglustat were diarrhoea, flatulence, abdominal pain, weight loss and tremor (see section 4.4). 
Najčešće nuspojave zabilježene u kliničkim ispitivanjima s miglustatom bile su proljev, flatulencija, bol u trbuhu, gubitak težine i tremor (vidjeti dio 4.4).
Miglustat has been studied in indications where certain events reported as adverse reactions, such as neurological and neuropsychological symptoms/signs, cognitive dysfunction and thrombocytopenia could also be due to the underlying conditions. 
Miglustat je ispitivan u indikacijama kod kojih su neki događaji koji su zabilježeni kao nuspojave, poput neuroloških i neurofizioloških simptoma/znakova, kognitivne disfunkcije i trombocitopenije mogli biti i posljedica bolesti od koje se bolesnik liječi.
Miglustat affected embryo/foetal survival in rats and rabbits, dystocia was reported, post-implantation losses were increased, and an increased incidence of vascular anomalies occurred in rabbits. 
Miglustat djeluje na preživljavanje embrija/fetusa u štakora i kunića, primijećena je distocija, porasli su gubitci nakon implantacije i došlo je do povećane incidencije vaskularnih anomalija kod kunića.
Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP. 
Ovaj lijek se ne smije upotrijebit nakon isteka roka valjanosti navedenog na kutiji iza oznake „Rok valjanosti”/„EXP”.
The neurological symptoms and thrombocytopenia could be due to the underlying disease. 
Neurološki simptomi i trombocitopenija mogu biti uzrokovani postojećom bolesti.
Sometimes your doctor will need to reduce the dose or stop Miglustat Dipharma treatment to stop the tremor. 
Ponekad će Vam liječnik reći da smanjite dozu ili potpuno prekinete liječenje lijekom Miglustat Dipharma kako bi otklonio tremor.
Contraceptive measures should be used by women of childbearing potential. 
Metode kontracepcije trebaju koristiti žene reproduktivne dobi.
The most common serious adverse reaction reported with miglustat treatment in clinical trials was peripheral neuropathy (see section 4.4). 
Najčešća ozbiljna nuspojava zabilježena liječenjem miglustatom u kliničkim ispitivanjima bila je periferna neuropatija (vidjeti dio 4.4).
The kinetics of miglustat appears to be dose linear and time independent. 
Pokazalo se da je kinetika miglustata linearno ovisna o dozi a neovisna o vremenu.
Do not give this medicine to children and adolescents (below 18 years old) with type 1 Gaucher disease because it is not known if it works in this disease. 
Ovaj lijek nemojte davati djeci ni adolescentima (mlađim od 18 godina) s Gaucherovom bolesti tipa 1
Cases of peripheral neuropathy have been reported in patients treated with miglustat with or without concurrent conditions such as vitamin B12 deficiency and monoclonal gammopathy. 
Kod bolesnika liječenih miglustatom zabilježeni su slučajevi periferne neuropatije prisutne bez ili sa popratnim stanjima kao što su pomanjkanje vitamina B12 i monoklonalna gamopatija.
• monitoring growth if you are a child or adolescent with Niemann-Pick type C disease 
• praćenje rasta ako ste dijete ili adolescent s Niemann-Pickovom bolesti tipa C • praćenje broja trombocita
Miglustat Dipharma should not be taken during breast-feeding. 
Miglustat Dipharma se ne smije uzimati tijekom dojenja.
If you have diarrhoea, your doctor may ask you to change your diet to reduce your lactose and carbohydrate intake such as sucrose (cane sugar), or not to take Miglustat Dipharma together with food, or to temporarily reduce your dose. 
Ako imate proljev liječnik može zatražiti prilagodbu prehrane kako biste smanjili uzimanje laktoze i drugih ugljikohidrata kao što je saharoza (šećer iz trske), ili neuzimanje lijeka Miglustat Dipharma s hranom ili privremeno smanjenje doze.
They could be signs of peripheral neuropathy, due to side effects of Miglustat Dipharma or they could be due to existing conditions. 
To mogu biti znakovi periferne neuropatije, koji se javljaju zbog nuspojava lijeka Miglustat Dipharma ili su se javili zbog postojeće bolesti.
Use of Miglustat Dipharma in patients with severe renal impairment (creatinine clearance < 30 ml/min/1.73 m2) is not recommended. 
Primjena lijeka Miglustat Dipharma kod bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina < 30 ml/min/1,73 m2) se ne preporučuje.
Overall the data show that treatment with miglustat can reduce the progression of clinically relevant neurological symptoms in patients with Niemann-Pick type C disease. 
Ukupni podatci pokazuju da liječenje miglustat može smanjiti progresiju klinički relevantnih neuroloških simptoma u bolesnika s Niemann-Pickove bolesti tipa C.
This study was conducted over a 6-month randomised comparison period followed by 18 months extension where all patients received miglustat monotherapy. 
To je ispitivanje provedeno u 6-mjesečnom randomiziranom komparativnom razdoblju nakon čega je slijedilo 18-mjesečni nastavak u kojem su svi bolesnici primali monoterapiju miglustatom.
Pack size of 84 capsules in non-perforated blisters. 
Veličina pakiranja od 84 kapsule u neperforiranim blisterima.
Miglustat Dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease (see sections 4.4, and 5.1). 
Miglustat Dipharma je indicirana za liječenje progresivne neurološke manifestacije u odraslih bolesnika i pedijatrijskih bolesnika s Niemann-Pickovom bolesti tipa C (vidjeti dijelove 4.4 i 5.1).
If you do get any of these effects reported above, please seek medical advice from your doctor as soon as possible. 
Ako imate bilo koju od tih nuspojava, zatražite savjet svog liječnika što je prije moguće.
Male patients should maintain reliable contraceptive methods while taking Miglustat Dipharma (see sections 4.4 and 5.3). 
Muški bolesnici trebaju primjenjivati pouzdane metode kontracepcije dok uzimaju lijek Miglustat Dipharma (vidjeti dijelove 4.4 i 5.3).
Growth should be monitored in paediatric and adolescent patients during treatment with Miglustat Dipharma; the benefit/risk balance should be re-assessed on an individual basis for continuation of therapy. 
U tijeku liječenja miglustat treba pratiti rast pedijatrijskih bolesnika i adolescenata; omjer koristi/rizika treba ponovo individualno procjenjivati za nastavak liječenja
• Miglustat Dipharma is also used to treat progressive neurological symptoms in NiemannPick type C disease in adults and in children. 
• Miglustat Dipharma se također primjenjuje za liječenje progresivnih neuroloških simptoma kod Niemann-Pickove bolesti tipa C u odraslih i djece
Tabulated list of adverse reactions Adverse reactions from clinical trials and spontaneous reporting, occurring in >1% of patients, are listed in the table below by system organ class and frequency (very common: ≥ 1/10, common: ≥ 1/100 < 1/10, uncommon: ≥1/1,000 to <1/100, rare: ≥1/10,000 to <1/1,000, very rare: <1/10,000). 
≥ 1/10, često: ≥ 1/100 i < 1/10, manje često: ≥ 1/1000 i < 1/100, rijetko: ≥ 1/10 000 i < 1/1000, vrlo rijetko: < 1/10 000).
Peripheral neuropathy, ataxia, amnesia, paraesthesia, hypoaesthesia headache, dizziness 
Periferna neuropatija, ataksija, amnezija, parestezija, hipoestezija, glavobolja, omaglica
Pharmacotherapeutic group: Other alimentary tract and metabolism products, various alimentary tract and metabolism products. 
Farmakoterapijska skupina: Ostali lijekovi za probavni sustav i metabolizam, različiti lijekovi za probavni sustav i metabolizam.
Elderly There is no experience with the use of miglustat in patients over the age of 70. 
Nema iskustava s primjenom miglustata u bolesnika starijih od 70 godina.
He or she may reduce the dose of Miglustat Dipharma or recommend other medicines to help control side effects. 
Liječnik može smanjiti dozu lijeka Miglustat Dipharma ili preporučiti drugi lijek koji bi pomogao kontrolirati te nuspojave.
The capsules are presented in PCTFE/PVC and Aluminium blister, ain pack size of 84 capsules in non-perforated blisters and 84x1 capsules in perforated unit dose blisters. 
PCTFE/PVC i aluminijskim blister pakiranjima, u veličini pakiranja od 84 kapsule u neperforiranim blisterima i 84x1 kapsula u perforiranim blisterima s jediničnim dozama.
Small mean reductions in haemoglobin [-0.95 g/dL (95% CI: -1.38, -0.53)] and platelet count [-44.1 × 109/L (95% CI: -57.6, -30.7)] were observed between baseline and end of study. 
1,38; -0,53)] i broja trombocita [-44.1 × 109/L (95% CI: -57,6; -30,7)].
For Niemann-Pick type C disease: For adults and adolescents (over 12 years old), the usual dose is two capsules (200 mg) three times a day (morning, afternoon and evening). 
• Za Niemann-Pickovu bolest tipa C: za odrasle i adolescente (starije od 12 godina) uobičajena doza su dvije kapsule (200 mg) tri puta dnevno (ujutro, popodne i navečer).